Alfredo Berruti1, Martin Fassnacht2, Harm Haak3, Tobias Else4, Eric Baudin5, Paola Sperone6, Matthias Kroiss7, Thomas Kerkhofs3, Andrew R Williams4, Arianna Ardito8, Sophie Leboulleux5, Marco Volante9, Timo Deutschbein7, Richards Feelders10, Cristina Ronchi7, Salvatore Grisanti11, Hans Gelderblom12, Francesco Porpiglia13, Mauro Papotti9, Gary D Hammer4, Bruno Allolio7, Massimo Terzolo8. 1. Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy. Electronic address: alfredo.berruti@gmail.com. 2. Department of Internal Medicine IV, University Clinic, Munich, Germany; Department of Medicine I, Endocrine Unit, University Hospital of Würzburg, Germany. 3. Internal Medicine, Maxima Medical Centre, Eindhoven, The Netherlands. 4. Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA. 5. Endocrine Oncology and Nuclear Medicine, Gustave Roussy Institute, Villejuif, France. 6. Department of Oncology, University of Turin, Medical Oncology Unit, San Luigi Gonzaga Hospital, Orbassano, Italy. 7. Department of Medicine I, Endocrine Unit, University Hospital of Würzburg, Germany. 8. Department of Clinical and Biological Sciences, University of Turin, Internal Medicine I, S. Luigi Gonzaga Hospital, Orbassano, Italy. 9. Department of Oncology, University of Turin, Pathology Unit, S. Luigi Gonzaga Hospital, Orbassano, Italy. 10. Erasmus MC, Rotterdam, The Netherlands. 11. Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy. 12. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands. 13. Department of Oncology, University of Turin, Urology Unit, S. Luigi Gonzaga Hospital, Orbassano, Italy.
Abstract
BACKGROUND: Although prognostic parameters are important to guide adjuvant treatment, very few have been identified in patients with completely resected adrenocortical carcinoma (ACC). OBJECTIVE: To assess the prognostic role of clinical symptoms of hypercortisolism in a large series of patients with completely resected ACC. DESIGN, SETTING, AND PARTICIPANTS: A total of 524 patients followed at referral centers for ACC in Europe and the United States entered the study. Inclusion criteria were ≥18 yr of age, a histologic diagnosis of ACC, and complete surgery (R0). Exclusion criteria were a history of other malignancies and adjuvant systemic therapies other than mitotane. INTERVENTION: All ACC patients were completely resected, and adjuvant mitotane therapy was prescribed at the discretion of the investigators. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was overall survival (OS). The secondary end points were recurrence-free survival (RFS) and the efficacy of adjuvant mitotane therapy according to cortisol secretion. RESULTS AND LIMITATIONS: Overt hypercortisolism was observed in 197 patients (37.6%). Patients with cortisol excess were younger (p=0.002); no difference according to sex and tumor stage was observed. The median follow-up of the series was 50 mo. After adjustment for sex, age, tumor stage, and mitotane treatment, the prognostic significance of cortisol excess was highly significant for both RFS (hazard ratio [HR]: 1.30; 95% confidence interval [CI], 1.04-2.62; p=0.02) and OS (HR: 1.55; 95% CI, 1.15-2.09; p=0.004). Mitotane administration was associated with a reduction of disease progression (adjusted HR: 0.65; 95% CI, 0.49-0.86; p=0.003) that did not differ according to the patient's secretory status. A major limitation is that only symptomatic patients were considered as having hypercortisolism, thus excluding information on the prognostic role of elevated cortisol levels in the absence of a clinical syndrome. CONCLUSIONS: Clinically relevant hypercortisolism is a new prognostic factor in patients with completely resected ACC. The efficacy of adjuvant mitotane does not seem to be influenced by overt hypercortisolism.
BACKGROUND: Although prognostic parameters are important to guide adjuvant treatment, very few have been identified in patients with completely resected adrenocortical carcinoma (ACC). OBJECTIVE: To assess the prognostic role of clinical symptoms of hypercortisolism in a large series of patients with completely resected ACC. DESIGN, SETTING, AND PARTICIPANTS: A total of 524 patients followed at referral centers for ACC in Europe and the United States entered the study. Inclusion criteria were ≥18 yr of age, a histologic diagnosis of ACC, and complete surgery (R0). Exclusion criteria were a history of other malignancies and adjuvant systemic therapies other than mitotane. INTERVENTION: All ACC patients were completely resected, and adjuvant mitotane therapy was prescribed at the discretion of the investigators. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was overall survival (OS). The secondary end points were recurrence-free survival (RFS) and the efficacy of adjuvant mitotane therapy according to cortisol secretion. RESULTS AND LIMITATIONS: Overt hypercortisolism was observed in 197 patients (37.6%). Patients with cortisol excess were younger (p=0.002); no difference according to sex and tumor stage was observed. The median follow-up of the series was 50 mo. After adjustment for sex, age, tumor stage, and mitotane treatment, the prognostic significance of cortisol excess was highly significant for both RFS (hazard ratio [HR]: 1.30; 95% confidence interval [CI], 1.04-2.62; p=0.02) and OS (HR: 1.55; 95% CI, 1.15-2.09; p=0.004). Mitotane administration was associated with a reduction of disease progression (adjusted HR: 0.65; 95% CI, 0.49-0.86; p=0.003) that did not differ according to the patient's secretory status. A major limitation is that only symptomatic patients were considered as having hypercortisolism, thus excluding information on the prognostic role of elevated cortisol levels in the absence of a clinical syndrome. CONCLUSIONS: Clinically relevant hypercortisolism is a new prognostic factor in patients with completely resected ACC. The efficacy of adjuvant mitotane does not seem to be influenced by overt hypercortisolism.
Authors: A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo Journal: J Endocrinol Invest Date: 2015-07-14 Impact factor: 4.256
Authors: Dwight H Owen; Sandipkumar Patel; Lai Wei; John E Phay; Lawrence A Shirley; Lawrence S Kirschner; Carl Schmidt; Sherif Abdel-Misih; Pamela Brock; Manisha H Shah; Bhavana Konda Journal: Horm Cancer Date: 2019-08-29 Impact factor: 3.869
Authors: Sean M Wrenn; T K Pandian; Rajshri M Gartland; Zhi Ven Fong; Matthew A Nehs Journal: Langenbecks Arch Surg Date: 2021-02-01 Impact factor: 3.445
Authors: M Batisse-Lignier; I Sahut-Barnola; F Tissier; T Dumontet; M Mathieu; C Drelon; J-C Pointud; C Damon-Soubeyrand; G Marceau; J-L Kemeny; J Bertherat; I Tauveron; P Val; A Martinez; A-M Lefrançois-Martinez Journal: Oncogene Date: 2017-04-03 Impact factor: 9.867
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958